Ayurvedic medicament classification depends on therapeutic use, not packaging, while related-person valuation needs proof of price influence.

Classification turned on the products' essential medicinal character and intended therapeutic use, not on attractive packaging or the presence of excipients, preservatives, fragrances, or other subsidiary cosmetic features; on that basis, the identified products were treated as ayurvedic medicaments, while the remaining products fell under cosmetics and toilet preparations. Related-person valuation required proof that common ownership or directorship actually influenced price, and comparable sales indicated no such influence; the manufacturer's price remained the valuation basis, subject to cum-duty treatment where duty was not separately recovered. The extended limitation period was unavailable because suppression or wilful misstatement was not established, so the demand beyond the normal period was time-barred.

---

---

Issues: (i) Whether the disputed products were classifiable as ayurvedic medicaments under CET sub-heading 3003.30 or as cosmetics and toilet preparations under Chapter 33; (ii) Whether the manufacturer and the marketing company were related persons so that the sale price to the marketing company could be adopted for valuation; (iii) Whether the extended period of limitation was invocable.

Issue (i): Whether the disputed products were classifiable as ayurvedic medicaments under CET sub-heading 3003.30 or as cosmetics and toilet preparations under Chapter 33.

Analysis: The decisive test was whether the products were intended to cure or prevent ailments, and whether their main ingredients were recognised Ayurvedic ingredients used in formulations with therapeutic or prophylactic value. The products could not be rejected merely because they were sold in attractive packs, had cosmetic use, or contained excipients, preservatives, fragrances, or bases. The labels and the expert evidence showed that several products were intended for treatment of skin and scalp ailments such as eczema, psoriasis, pigmentation, dandruff, acne, alopecia, infections, and similar conditions. Applying the distinction between cosmetics and medicaments, and the principle that the presence of subsidiary cosmetic utility does not displace the medicinal character where therapeutic use is established, the Tribunal accepted classification as ayurvedic medicaments for the identified products.

Conclusion: The identified 22 products were held to be P & P ayurvedic medicaments under CET sub-heading 3003.30, while the remaining products remained classifiable as cosmetics and toilet preparations under Chapter 33.

Issue (ii): Whether the manufacturer and the marketing company were related persons so that the sale price to the marketing company could be adopted for valuation.

Analysis: Common directors or links between companies were held insufficient by themselves to establish related-person status. The price charged by the manufacturer could be discarded only if the relationship actually influenced the price. The record showed sales to hotels and other buyers at comparable or identical prices, and the evidence did not establish depression of the price charged to the marketing company. For valuation, the sale price had also to be treated as cum-duty where duty had not been separately recovered. In the connected matter involving IRL Marketing, the same reasoning applied and the parties were not treated as related persons.

Conclusion: The companies were not related persons, and the manufacturer's sale price was to be adopted as the basis for valuation, subject to cum-duty abatement.

Issue (iii): Whether the extended period of limitation was invocable.

Analysis: The Tribunal found that suppression or wilful misstatement was not established. The authorities had approved the classification list, the drug control authorities had permitted continued manufacture under the licence, and a trade notice had clarified that preservatives, excipients, and minor non-therapeutic ingredients did not by themselves defeat the claim to exemption or medicinal classification. In these circumstances, the ingredients necessary to invoke the extended period were absent.

Conclusion: The extended period of limitation was not applicable, and the demand for the period beyond the normal limitation was time-barred.

Final Conclusion: The appeals succeeded in part: the Tribunal upheld medicinal classification for the identified products, rejected related-person valuation, denied invocation of the extended limitation, set aside the penalties and confiscation, and directed re-quantification only for the products finally held to be dutiable within the normal period.

Ratio Decidendi: For excise classification, a product is to be treated according to its essential medicinal character and intended therapeutic use, and not merely by its packaging, subsidiary cosmetic utility, or the presence of non-therapeutic excipients; valuation cannot be altered on the basis of inter-company dealings unless influence on price is proved; and the extended period requires clear proof of suppression or misstatement.

---